Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT04499755
Recruiting Phase 3

Efficacy of Nucleo CMP Forte in Traumatic Brain Injury in Pediatrics

NCT04499755 · tracked via the Priya Life Science Egypt tracker
Sponsor
Sherief Abd-Elsalam
Phase
Phase 3
Started
2020-06-01
Last updated
2020-08-05

Condition(s) studied

Brain Injuries

Investigational drug(s) / intervention(s)

Nucleo CMP Forte

Nucleo CMP Forte: Nucleo CMP Forte twice daily for 6 weeks

Study summary

Efficacy of Nucleo CMP Forte in Traumatic Brain Injury in Pediatrics

Eligibility

Sex
ALL
Min age
—
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria: * Children with traumatic brain injury: Moderate and Severe. Exclusion Criteria: * Underlying CNS disorders,

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Sherief Abd-Elsalam Tanta Egypt Recruiting

More Sherief Abd-Elsalam trials in Egypt

Role of Point of Care Ultrasound in Endotracheal Tube Placement Recruiting
Citicoline as Neuroprotector in Preterm Recruiting
Pantoprazole in Cisplatin Nephrotoxicity Recruiting
Utility of Some Novel Biomarkers of Patients With Chronic Heart Failure Recruiting
Mebendazole as Adjuvant Treatment for Colon Cancer Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04499755 on ClinicalTrials.gov ↗ ← All trials in Egypt